39th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150265553 | Methods and Materials for the Treatment of Testosterone Deficiency in Men - The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism. | 2015-09-24 |
20150265554 | Treatment of MeCP-2 Associated Disorders - The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome. | 2015-09-24 |
20150265555 | Chemosensory Receptor Ligand-Based Therapies - Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use. | 2015-09-24 |
20150265556 | METHOD OF SUPPLEMENTING THE DIET AND AMELIORATING OXIDATIVE STRESS - A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of an active compound having the chemical structure: | 2015-09-24 |
20150265557 | COMPOUNDS FOR THE TREATMENT AND PREVENTION OF RETROVIRAL INFECTIONS - The present invention provides compounds and pharmaceutical compositions for use in treating or preventing retroviral infections, in particular HIV infections and/or diseases associated with an HIV infection. | 2015-09-24 |
20150265558 | TREATMENT OF ADHD - A method is provided for treating a subject in need of therapy for attention deficit hyperactivity disorder (ADHD) and related CNS disorder symptoms of impaired learning, impaired planning, impaired problem solving, impulsiveness, attention deficit and aggression comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such behavioural disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM. | 2015-09-24 |
20150265559 | BENZOATES FOR USE IN TREATING DEMENTIA - A method for treating a subject afflicted with dementia is disclosed. The method comprises administering to the subject a composition comprising an effective amount of a benzoic acid, a salt, an ester, or a derivative thereof, and a pharmaceutically acceptable carrier or vehicle, wherein the subject is not administered any other neuropharmaceutical. | 2015-09-24 |
20150265560 | Treatment of Intrahepatic Cholestatic Diseases - Treatment of intrahepatic cholestatic diseases by therapy with MBX-8025 or an MBX-8025 salt. | 2015-09-24 |
20150265561 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) - Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke or ischemia, or treating gastric inflammation. | 2015-09-24 |
20150265562 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 2015-09-24 |
20150265563 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field - The present invention relates to compounds comprising the general formula (I), in which R | 2015-09-24 |
20150265564 | BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS - Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Apel/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Apel/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Apel/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Apel/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component. | 2015-09-24 |
20150265565 | METHODS OF TREATING CHRONIC DRY EYE DISEASE USING C16:1n7-PALMITOLEATE AND DERIVATIVES THEREOF - The present technology provides methods for preventing or treating dry eyes in a subject in need thereof. The methods include administering to the subject an effective amount of a composition comprising C16:1n7-palmitoleate, its derivatives, pharmaceutically acceptable salts thereof, or a combination thereof. | 2015-09-24 |
20150265566 | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 2015-09-24 |
20150265567 | Method for Treating Skin Lesions with Ingenol Mebutate - The invention provides novel methods for topical treatment of skin lesions such as actinic keratosis over treatment areas up to 250 cm | 2015-09-24 |
20150265568 | PHARMACEUTICAL COMPOSITION COMPRISING PALMITOYLETHANOLAMIDE AND L-ACETYLCARNITINE - A pharmaceutical composition, for use in humans or animals, containing N-palmitoylethanolamide for the control of the inflammatory and/or neuropatic pain of various origin. In particular, the present invention relates to a pharmaceutical composition comprising palmitoylethanolamide (PEA) and L-acetylcarnitine (LAC), optionally in addition with an antioxidant compound, such as a polyphenol, alpha-lipoic acid, and L-acetylcysteine. | 2015-09-24 |
20150265569 | Treatment for Ischemic Stroke - Granulocyte colony-stimulating factor (G-CSF; a stem cell enhancer and facilitator), DETC-MeSO (a glutamate receptor partial antagonist and anti-excitotoxicity agent), and sulindac (a potent anti-oxidant and anti-inflammatory agent) each can protect brain tissue exposed to a cerebral ischemia/reperfusion injury, and minimize the size of infarcts that develop as a result of the injury. When administered in combination, these agents are effective at protecting brain tissue and minimizing the size of an infarct resulting from the injury at much lower concentrations compared to using a single agent. | 2015-09-24 |
20150265570 | TRANSMUCOSAL DELIVERY OF TOCOTRIENOL - The present invention relates to pharmaceutical compositions formulated for transmucosal delivery, and in particular sublingual delivery, comprising at least one tocotrienol or derivative thereof together with one or more pharmaceutically acceptable excipients. The present further relates to the use of said compositions for treating or preventing post exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy, conditions resulting from radiation exposure, stabilizing and/or controlling blood glucose levels, and improving exercise endurance and capacity. | 2015-09-24 |
20150265571 | USE OF DELTA TOCOPHEROL FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS - This disclosure relates generally to the treatment of lysosomal storage disorders. Specifically, the disclosure relates to a novel use of δ tocopherol in the treatment of diseases and conditions related to lysosomal storage disorders. Included in the present disclosure is a method for the modulation of cholesterol recycling. Further, the disclosure relates to conditions such as Niemann-Pick type C disease, Farber disease, Niemann-Pick type A disease, Wolman disease and Tay Sachs disease. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol. Further included in the present disclosure is a method for treating lysosomal storage disorders comprising the administration of δ tocopherol in combination with cyclodextrin to a patient in need thereof. | 2015-09-24 |
20150265572 | INJECTABLE CANCER COMPOSITIONS - Provided herein are therapeutic prodrug compositions which may be delivered to a patient via an injectable emulsion, comprising a therapeutic drug linked to a peptide that is efficiently and specifically cleaved by a selected protease associated with a cell proliferative disorder, including cancer cells, for example, prostate, liver or breast cancer cells, in a patient. Also provided herein are methods of treating cell proliferative disorders, including cancers, with the therapeutic prodrug compositions. | 2015-09-24 |
20150265573 | COUMARIN COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2015-09-24 |
20150265574 | PHARMACEUTICAL COMPOSITION COMPRISING OMEGA-3 FATTY ACID AND HYDROXY-DERIVATIVE OF A STATIN AND METHODS OF USING SAME - In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof. | 2015-09-24 |
20150265575 | PHARMACEUTICAL COMPOSITION ON THE BASIS OF PHYTO-NUTRIENTS WITH INCREASED BIOAVAILABILITY, HAVING ANTI-TUMOR ACTIVITY, AND METHOD FOR PRODUCING SAID COMPOSITION (ALTERNATIVES) - A pharmaceutical composition for peroral delivery of phyto-nutrients includes at least one phyto-nutrient from the following series: epigallocatechin-3-gallate, diindolylmethane, genestein, resveratrol, curcumine, and a solubilizer—a polyvinylcaprolactam/polyvinylacetate/polyethyleneglycol graft copolymer with an average molecular mass of 90000-140000 g/mol at a mass ratio of at least one phyto-nutrient and solubilizer of 1/5 to 1/1. The composition can additionally include a pharmaceutically acceptable carrier. The composition may be produced by dissolving the solubilizer in an organic solvent, dissolving at least one phyto-nutrient in the same organic solvent, mixing the resulting solutions, and distilling off the solvent in vacuo. The resulting mixture is heated to 45-50° C. with constant stirring and, after distillation, the product is dried in vacuo. Ethanol, acetone, or isopropanol can be used as the organic solvent. Alternatively, the composition may be produced by dry mixing the powders of the solubilizer and of at least one phyto-nutrient. | 2015-09-24 |
20150265576 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO - The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT | 2015-09-24 |
20150265577 | ANTI-CANCER COMPOSITIONS AND METHODS - Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor. | 2015-09-24 |
20150265578 | ALPHA ADRENERIC RECEPTOR AGONISTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE - Effective treatments of pain and/or inflammation from degenerative disc disease and/or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and/or facet joint, one can reduce, prevent or treat pain and/or inflammation caused by the degenerative disc disease and/or facet joint. | 2015-09-24 |
20150265579 | CANDESARTAN CILEXETIL-CONTAINING PREPARATION - A candesartan cilexetil-containing preparation contains candesartan cilexetil and lauromacrogol. The lauromacrogol may be contained at a ratio of 2.4 parts by weight or less with respect to 100 parts by weight of the candesartan cilexetil-containing preparation. The candesartan cilexetil-containing preparation may further contain at least one kind of pharmacologically acceptable additives among a diluent, a disintegrant and a binder. | 2015-09-24 |
20150265580 | DOSING REGIMEN FOR A SELECTIVE S1P1 RECEPTOR AGONIST - The present invention relates to a dosing regimen for a selective S1P | 2015-09-24 |
20150265581 | FORMULATIONS AND METHODS FOR VASCULAR PERMEABILITY-RELATED DISEASES OR CONDITIONS - Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability. | 2015-09-24 |
20150265582 | RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS - The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof. | 2015-09-24 |
20150265583 | Treatment of Cognitive Disorders with (R)-7-Chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-Carboxamide and Pharmaceutically Acceptable Salts Thereof - (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses to improve cognition. | 2015-09-24 |
20150265584 | LEVUGLANDIN ADDUCTS HISTONE H4 IN A CYCLOOXYGENASE-2-DEPENDENT MANNER, ALTERING ITS INTERACTION WITH DNA - Method of inhibiting formation of levuglandin adducts of histone and DNA in a subject in need thereof by administering a levuglandin adduct formation inhibiting amount of a compound of the following formula: | 2015-09-24 |
20150265585 | Method of Treating Skin Disorders - A skin care product includes a compound of Formula I, IA, or IB (e.g., anatabine), or a salt thereof, and a suitable cosmetic or pharmaceutical vehicle. In some aspects, the skin care product is a paste, cream, lotion, gel, moisturizer, cleanser, or sunscreen. In some embodiments, the skin care product is applied topically to reduce inflammation, redness, and/or irritation, and/or to improve the appearance of the skin. In other embodiments, the skin care product is applied topically to treat an autoimmune and/or dermatological condition such as acne, psoriasis, and/or rosacea. | 2015-09-24 |
20150265586 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR - Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof. | 2015-09-24 |
20150265587 | ANDROGEN RECEPTOR VARIANTS AND METHODS FOR MAKING AND USING - The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation. | 2015-09-24 |
20150265588 | COMBINATION OF AN ANTI-CANCER AGENT SUCH AS A TYROSINEKINASE INHIBITOR AND A STAT5 ANTAGONIST, PREFERABLY A THIAZOLIDINEDIONE, FOR ELIMINATING HEMATOLOGIC CANCER STEM CELLS IN VIVO AND FOR PREVENTING HEMATOLOGIC CANCER RELAPSE - Provided are methods for eliminating hematologic cancer stem cells in vivo, and thus preventing cancer relapse. The methods comprise a Signal Transducer and Activator of Transcription 5 (STAT5) antagonist (e.g., a PPARy agonist) after the patient has had ana initial course of treatment with an anti-cancer agent (e.g., a TKI), to eliminate residual cancer stem cells which cause re lapse. | 2015-09-24 |
20150265589 | PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK - The present invention relates to a compound of formula (I): | 2015-09-24 |
20150265590 | COMPOSITIONS AND METHODS FOR TREATING MAMMARY TUMORS - The present invention provides methods of inhibiting abnormal growth of cells, with the methods comprising contacting the cells with at least one of the sensitizing compounds disclosed herein in an amount sufficient to inhibit cell growth. The present invention also provides methods of treating and/or reducing the likelihood of being diagnosed with breast cancer, with the methods comprising administering to a subject in need of treatment thereof at least one of the sensitizing compounds disclosed herein. | 2015-09-24 |
20150265591 | METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF CERTAIN LEUKEMIAS - Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed. | 2015-09-24 |
20150265592 | USE OF HIGH DOSE LAQUINIMOD FOR TREATING MULTIPLE SCLEROSIS - Disclosed herein are methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, methods for treating a human subject by providing neuroprotection to the human subject, and methods of treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient, comprising orally administering to the human patient or subject a daily dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof. The subject invention also provides a pharmaceutical oral unit dosage form of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome, for use in treating a human subject by providing neuroprotection to the human subject, or for use treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome by increasing the time to confirmed disease progression, increasing the time to confirmed relapse or reducing brain atrophy in the human patient. | 2015-09-24 |
20150265593 | METHODS AND COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION - Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors. | 2015-09-24 |
20150265597 | Oxycodone Compositions - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2015-09-24 |
20150265598 | Oxycodone Compositions - In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. | 2015-09-24 |
20150265602 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-09-24 |
20150265603 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-09-24 |
20150265604 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-09-24 |
20150265605 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-09-24 |
20150265606 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-09-24 |
20150265607 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2015-09-24 |
20150265608 | Compounds for Treating Rac-GTPase Mediated Disorder - This disclosure relates to compositions including certain compounds identified by a quantitative, high throughput assay to be effective in the treatment of chronic myelogenous leukemia, as well as methods for the manufacture of and the use of these compounds for treating a Rac-GTPase mediated disorder. | 2015-09-24 |
20150265609 | TERCONAZOLE COMPOSITION AND METHOD - An aqueous terconazole composition comprises at least about 0.4 percent by weight of terconazole dissolved in water, and a terconazole crystallization-inhibiting amount of citric acid. The composition is free from terconazole crystals at an ambient temperature of about 20° C. Methods of preparing the composition are also described. The compositions provide for improved therapeutic release of terconazole. | 2015-09-24 |
20150265610 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 2015-09-24 |
20150265611 | PHARMACEUTICAL COMPOSITION - A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied. | 2015-09-24 |
20150265612 | HETEROARYL DERIVATIVES AS CFTR MODULATORS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2015-09-24 |
20150265613 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME - The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids. | 2015-09-24 |
20150265614 | ORAL PREPARATION AND METHOD FOR PRODUCING THE SAME - An oral preparation including: a porous disintegrative template; and an active ingredient supported in the pores of the disintegrative template, is excellent in physical/chemical stability, processibility, and fast-acting property as compared to the existing dosage form, and may block unpleasantness due to a bitter taste during the internal use and meet the medicine-taking compliance. | 2015-09-24 |
20150265615 | PHARMACEUTICAL COMPOSITIONS - A composition of an antitussive, a decongestant, or an antihistamine to treat upper respiratory and oral pharyngeal congestion and related symptoms in a patient. | 2015-09-24 |
20150265616 | Pharmaceutical Combinations Comprising a B-RAF Inhibitor, and EGFR Inhibitor and Optionally a PI3K-Alpha Inhibitor - A pharmaceutical combination comprising (a) a B-Raf inhibitor, (b) a EGFR inhibitor and, optionally, (c) a PI3K inhibitor; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination. | 2015-09-24 |
20150265617 | PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME - Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein. | 2015-09-24 |
20150265618 | INHIBITORS OF BRUTON'S TYROSINE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2015-09-24 |
20150265619 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY - Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof. | 2015-09-24 |
20150265620 | ANIMAL FEED SUPPLEMENT COMPRISING RACTOPAMINE AND CAFFEINE - An animal feed supplement comprising a synergistic combination of ractopamine and caffeine and a method of increasing feed efficiency of a pig using the animal feed supplement is described. | 2015-09-24 |
20150265621 | Treating Bronchiectasis With Doxofylline and Erdosteine - A method and pharmaceutical composition for the treatment of bronchiectasis comprising doxofylline and erdosteine. | 2015-09-24 |
20150265622 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND THERAPY FOR MINIERE'S DISEASE - Provided are articles of manufacture, compositions and methods for prophylaxis and/or therapy for disorders involving dizziness and/or vertigo. The articles of manufacture and compositions contain lamotrigen and/or bupropion. The compositions include pharmaceutical compositions which are intended to alleviate dizziness and/or vertigo. In certain aspects the disclosure includes articles of manufacture and kits which include printed material which provides an indication that the articles or compositions are intended to be used for prophylaxis and/or therapy of Meniere's Disease or a symptom thereof. | 2015-09-24 |
20150265623 | USE OF 1-ADAMANTYLETHYLOXY-3-MORPHOLINO-2-PROPANOL OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PHARMACEUTICAL COMPOSITIONS AS A NEURORETINAL PROTECTOR - The use of 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml in pharmaceutical compositions for parenteral administration in the treatment of degenerative neuroretinal diseases of various geneses. | 2015-09-24 |
20150265624 | TREATMENT OF EPILEPTIC DISORDERS IN FELINE ANIMALS - The present invention relates to the use of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2.5-dihydro-1H-imidazol-2-one or a physiologically acceptable salt thereof in a method for treatment and/or prevention of one or more epileptic disorders in a feline animal, preferably a cat. | 2015-09-24 |
20150265625 | (ALPHA-SUBSTITUTED ARALKYLAMINO AND HETEROARYLALKYLAMINO) PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES - Provided herein are (alpha-substituted aralkylamino or heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula I, and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases. | 2015-09-24 |
20150265626 | METHODS OF TREATING DISORDERS ASSOCIATED WITH PROTEIN AGGREGATION - The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a | 2015-09-24 |
20150265627 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES - The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). | 2015-09-24 |
20150265628 | GENOMIC TESTING FOR EFFECTIVE THERAPIES AND DETERMINATION OF DOSING STRATEGY - Several embodiments disclosed herein relate to methods for calculating a dosing regimen that is tailored specifically to the genetic and metabolic profile of a particular patient. In some embodiments, the dosing regimen is related to administration of the antipsychotic drug clozapine, and the tailoring of the regimen reduces risk of adverse side effects. | 2015-09-24 |
20150265629 | USE OF ELECTROPHILIC COMPOUNDS FOR INDUCING PLATELET PRODUCTION OR MAINTAINING PLATELET FUNCTION - The present invention is directed to a method of inducing platelet production that includes contacting a megakaryocyte with an electrophilic compound under conditions effective to induce platelet production by the contacting megakaryocyte. Methods of treating a patient for low platelet levels, increasing the circulating half-life of platelets, and improving the quality (activity) of platelets are also disclosed herein, which involve administering the electrophilic compound to a patient an effective amount to achieve the desired effect. Pharmaceutical compositions and therapeutic systems are also disclosed for carrying out these therapeutic treatments. | 2015-09-24 |
20150265630 | 6-Substituted Estradiol Derivatives for the Treatment of Alzheimer's Disease - Disclosed is a method of treating Alzheimer's Disease with 6-substituted estradiol compounds of the formula | 2015-09-24 |
20150265631 | PHARMACEUTICAL COMPOSITION FOR THE SUBLINGUAL ADMINISTRATION OF PROGESTERONE, AND METHOD FOR ITS PREPARATION - A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described. | 2015-09-24 |
20150265632 | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION - The present disclosure teaches generally neuroprotection and in particular the use of non-hormonal neuroactive steroids to ameliorate inflammation of the central nervous system (CNS). More specifically, the present claims define methods of treating inflammation or ameliorating a neuroinflammatory-promoting condition in the CNS by administration of a steroid with certain properties formulated in a sulfobutyl ether beta-cyclodextrin composition. The steroid is neuroactive, devoid of hormonal endocrine activity and activates a pregnane X receptor. Examples of such steroids include alphaxalone, alphadolone allopregnanolone, pregnanolone, ganaxolone, hydroxydione, minaxolone, Org20599, Org21465, CT1341 and compounds of Formula (I). Dependent claims further define the type of the neuroinflammatory-promoting conditions, the type of cyclodextrin, the molar ratio of neuroactive steroid to the cyclodextrin and the inclusion of other active agents or excipients in the composition and their nature. | 2015-09-24 |
20150265633 | STEROID CONTAINING DRUG DELIVERY SYSTEM - Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed. | 2015-09-24 |
20150265634 | SOLID DRUG DELIVERY APPARATUS, FORMULATIONS AND METHODS OF USE - Embodiments provide apparatus and methods for delivering solid form medications such as pellets to various locations in the body. One embodiment provides an apparatus for in vivo delivery of medication pellets comprising a housing including a port, a pellet-containing belt disposed in the housing, and a mechanism for transferring the pellets from the belt to a delivery site (DS) outside the housing. Each pellet contains a dose of drug to treat a medical condition. An elongate member is coupled to the housing and includes a lumen for pellet delivery, a proximal end coupled to the port and a distal end positioned at the DS. The pellet can be delivered to the DS at regular intervals or responsive to a detected biological event. Embodiments of the invention are particularly useful for delivering medication to treat a medical condition over an extended period without requiring a patient to take external medication. | 2015-09-24 |
20150265635 | 9-SUBSTITUTED MINOCYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 2015-09-24 |
20150265636 | COMPOSITIONS AND METHODS FOR TREATING ADDICTION - This invention relates to compositions containing combinations of a balanced PC composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from addiction to substances and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans. | 2015-09-24 |
20150265637 | METHODS AND COMPOSITIONS FOR TREATING SYMPTOMS OF DISEASES RELATED TO IMBALANCE OF ESSENTIAL FATTY ACIDS - This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans. | 2015-09-24 |
20150265638 | ABSORPTION OF FAT-SOLUBLE NUTRIENTS - A method of preparing a feed composition includes (a) mixing one or more carotenoids and one or more phospholipids in an organic solvent to form a solution; and (b) thereafter combining the carotenoid(s) and phospholipid(s) with at least one other animal feed component. The organic solvent is a polar solvent selected from the group consisting of chlorocarbons and lower alcohols, and step (a) further includes removing the polar solvent from the solution. | 2015-09-24 |
20150265639 | PROCESSES FOR THE PREPARATION OF PHOSPHOLIPID-ENRICHED DAIRY PRODUCTS AS NEUTRACEUTICALS FOR THE FORMULATION OF FUNCTIONAL FOODS - The present invention discloses processes for the preparation of phospholipid-enriched dairy products as nutraceuticals for the formulation of functional foods, the processes include the steps of: combining a non-dairy-based PL-containing material, having phosphatidylserine (PS) or phosphatidic acid (PA) in the PL-containing material, with water and an oil component to form a paste; removing an excess amount of the water from the paste to form a PL-oil solution; and mixing the PL-oil solution with a dairy component, thereby obtaining a PL-enriched dairy product. Preferably, the PS or the PA is derived in part from an enzymatically-processed lecithin. Preferably, the step of combining is performed at a weight-to-weight (w-w) concentration of at least about 2% of the water to said PL-containing material. Preferably, the PL-oil solution has a weight-to-weight (w-w) concentration of at least about 0.01% of a residual amount of the water to the PL-containing material. | 2015-09-24 |
20150265640 | LIPIODOL-BASED ANTI-TUMOUR EMULSION FOR TREATING CANCER - The present invention relates to a pharmaceutical composition including Lipiodol and a molecule with anti-tumour activity and secondarily a hydroxyethyl starch. The present invention also relates to the use of the compositions according to the invention for treating cancer. According to one embodiment, the pharmaceutical composition according to the invention has between 0.004% and 0.2% by weight of idarubicin, between 0.38% and 2.25% by weight of hydroxyethyl starch and secondarily between 60% and 68% by weight of Lipiodol, and water for injection (or even physiological saline) in a quantity sufficient (q.s.) for 100%. | 2015-09-24 |
20150265641 | Methods for the Effective Treatment of Metastatic Cancer - The present invention relates to methods for the treatment of metastatic cancer. Methods of treating metastatic cancer by administration of a set of drugs overcome multiple mechanisms of melphalan resistance and hypersensitize cancer cells to melphalan are described. The methods involve the administration of drug(s) that induce oxidative stress in cancer cells, in conjunction with melphalan on a defined schedule. | 2015-09-24 |
20150265642 | NAD BIOSYNTHESIS AND PRECURSORS IN THE PREVENTION AND TREATMENT OF INFLAMMATION - Disclosed herein are novel compositions and methods for the treatment of age-related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also described herein are methods for the identification of agents useful in the foregoing methods. | 2015-09-24 |
20150265643 | ABSORBABLE CRYSTALLINE COPOLYESTER-BASED BIOACTIVE HYDROFORMING LUMINAL LINER COMPOSITIONS - Bioactive, hydroforming luminal liner compositions are formed of high molecular weight crystalline, absorbable copolyesters dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty. | 2015-09-24 |
20150265644 | THERAPEUTIC METHODS AND COMPOSITIONS FOR TREATING DIABETES UTILIZING DITERPENOID COMPOUNDS - The present invention is directed to therapeutic methods and compositions for treating insulin resistant diabetes or diabetes with inflammation in a subject comprising administering an effective amount of borapetoside A, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, to said subject. | 2015-09-24 |
20150265645 | Composition For Prevention, Amelioration Or Treatment Of Metabolic Syndrome - A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein | 2015-09-24 |
20150265646 | Edible Energy Composition - The disclosure relates to an edible energy composition that provides physical and mental benefits when ingested. | 2015-09-24 |
20150265647 | URIDINE DIPHOSPHATE DERIVATIVES, PRODRUGS, COMPOSITIONS AND USES THEREOF - This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis. | 2015-09-24 |
20150265648 | HYALURONAN AS A CHEMO-SENSITIZER IN THE TREATMENT OF CANCER - This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer. | 2015-09-24 |
20150265649 | STRONTIUM COMPOUND FOR TREATMENT OF SUB-DERMAL SOFT TISSUE PAIN - The invention provides a method of treatment of a human or non-human subject to combat sub-dermal soft tissue pain therein, said method comprising administering to a subject in need thereof an effective amount of a physiologically tolerable strontium compound. | 2015-09-24 |
20150265650 | METHODS FOR ENHANCING THE EFFECT OF EGCG ON MITIGATING SKELETAL MUSCLE LOSS - Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate (“EGCg”) in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc. | 2015-09-24 |
20150265651 | Herbal Composition for the Prevention and Treatment of TNF-ALPHA Mediated Diseases - The present invention relates to a herbal composition for use in the prevention or treatment of a disease mediated by TNF-α. The present invention also provides a method for the preparation of the herbal composition and methods for using such herbal composition. | 2015-09-24 |
20150265652 | PRODUCTION OF MIDBRAIN DOPAMINERGIC NEURONS AND METHODS FOR THE USE THEREOF - Methods are provided for efficient production of midbrain dopaminergic (DA) neurons. In some aspects, methods involve differentiation and selection of DA neurons for a transgenic pluripotent cell population (e.g., cells comprising a selectable marker gene). Cell populations produced by the instant methods and methods of their use are likewise provided. | 2015-09-24 |
20150265653 | Artificial Skeletal Material and Constructs Formed Therefrom - A bioresorbable skeletal construct member formed from an osteoinductive composition comprising autogenic bone and an extracellular matrix (ECM) material, the construct member being configured to induce osteoanagenesis and angiogenesis when implanted proximate endogenous bone and tissue. | 2015-09-24 |
20150265654 | METHOD FOR THE TREATMENT OF DAMAGED TISSUE - The present invention provides a method for treating a subject animal having a damaged tissue. In one aspect of the invention, the method includes the steps of harvesting a tissue sample from a tissue source; growing a plurality of cells from the tissue sample in a culture system; obtaining a sample of the grown cells from the culture system; and introducing the sample of the grown cells into the subject animal for aiding in repair of the damaged tissue; wherein the introducing step includes introducing the sample of the grown cells into a region of the subject animal not including the damaged tissue. | 2015-09-24 |
20150265655 | EXTRACT AND FORMULATION INCLUDING EXTRACT - It is an object of the present invention to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus wherein the quality is more stabilized, and a preparation containing the extract, etc. The use of the amount of N-acetylneuraminic acid contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and a preparation containing the extract as an index makes possible to warrant the quality of each manufacturing lot of the extract and the preparation in more stable manner. The extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing the extract which are manufactured as above, and in which the quality thereof becomes more stable, are warranted to maintain efficacy and safety in more strict manner, and thus extremely useful. | 2015-09-24 |
20150265656 | HUMAN ENDOCRINE PROGENITORS FROM ADULT PANCREATIC TISSUE - The present invention relates to the field of progenitor cells. More specifically, the present invention provides compositions and methods for isolating endocrine progenitor cells from pancreatic tissue. In certain embodiments, the method comprises the steps of (a) providing a pancreatic tissue sample; (b) isolating cells positive for CD133+; and (c) culturing the isolated cells in defined media for at least about 4 days. | 2015-09-24 |
20150265657 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 2015-09-24 |
20150265658 | AGENT FOR ACTIVATING SIRTUIN GENE CONTAINING EGG SHELL MEMBRANE INGREDIENT AND COMPOSITION USING THE SAME - Providing an agent for activating a sirtuin gene and an application thereof. The agent for activating a sirtuin gene is characterized to contain an egg shell membrane ingredient, for example an egg shell membrane-containing powder or soluble egg shell membrane ingredient. | 2015-09-24 |